Thienopyrimidinone NMDA receptor modulators and uses thereof
US11541057B2 · kind B2 · utility
1Cited by
8References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 26, 2021 |
| Grant date | Jan 3, 2023 |
| Priority date | — |
| Expiry date | Mar 12, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein, in part, are methods of treating neurological disorders, e.g., schizophrenia and major depressive disorder, comprising administering an effective amount of a disclosed heterocyclic compound. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.